Introduction {#s1}
============

Cancer immune surveillance is an important process by which the immune system can eliminate nascent tumor cells and to control tumor evolution. Eventually, due to the genetic instability, new tumor cell variants can become resistant to immune effector cells by decreasing their immunogenicity and/or secreting and recruiting immunosuppressive factors in the tumor microenvironment (TME). During this phase of equilibrium, if the immune system is unable to eliminate these clonal variants, then tumors evolve mechanisms to escape from the immune attack allowing malignant progression ([@B1], [@B2]). These mechanisms are diverse but primarily induce attenuation of anti-tumor CD8^+^ T lymphocyte. Immunosuppressive myeloid cells, including myeloid-derived suppressor cells (MDSCs) are key mediators in assisting tumors to escape immune surveillance, contributing to tumor development and progression. MDSCs are a heterogeneous group of immature myeloid cells (IMCs) with strong immunosuppressive patterns and functions. Under normal condition, IMCs quickly differentiate into mature granulocytes, macrophages, or dendritic cells (DCs) which play essential roles in host defense against pathogens. However, in a variety of pathologic conditions such as inflammation, cancer and infection IMCs fail their normal differentiation and acquire the features of immature and dysfunctional myeloid population, which include MDSCs ([@B2]). Recently, it has been introduced the hypothesis that MDSCs could also be derived from mature myeloid cells such as monocytes and neutrophils in cancer settings ([@B3], [@B4]). In particular, it has been demonstrated that CD14^+^ cells exposed to extracellular vesicles (EVs) (containing proteins, lipids, and genetic material) isolated from melanoma cells, show a suppressive activity on T cells thus referred as EV-MDSCs. Similarly, it has been reported that the treatment of healthy donor-derived monocytes with chronic lymphocytic leukemia (CLL) cells-derived exosomes induced MDSCs functional characteristics on monocytes mainly driven by miRNA-155 ([@B5]). Thus, deregulated myelopoiesis is a common occurrence in cancer and it is accompanied by a reciprocal decline in the quantity/quality of the lymphoid response ([@B6]). Myelopoiesis is a tightly controlled process. Certain transcription factors, such as CCAAT/enhancer binding protein-α (C/EBPα), and interferon regulatory factor-8 (IRF-8), are instrumental for normal myeloid cell development, differentiation and function and they can be targets of tumor-derived factors (TDFs). Thus, such TDFs may impair their expression, which ultimately affect the fate of the resulting myeloid response. Indeed, interventions that target atypical myelopoiesis by enhancing IRF-8 expression demonstrated to abrogate MDSC-mediated immunosuppression and to promote MDSCs differentiation in effector myeloid cells including DCs and mature neutrophils with anti-tumor activity ([@B7]--[@B9]). About 10 years ago, two major subsets of MDSCs have been identified based on their phenotypic and morphological features: monocytic-MDSCs (M-MDSCs) and granulocytic-MDSCs (G-MDSCs). G-MDSCs are phenotypically and morphologically similar to neutrophils, whereas M-MDSCs are similar to monocytes ([@B10]). In tumor-bearing mice these cells are characterized by the expression of CD11b and Gr-1 surface markers. The granulocyte marker Gr-1 includes the isoforms Ly6C and Ly6G, and these subsets can be more accurately identified based on their expression as CD11b^+^Ly6C^hi^Ly6G^−^ (M-MDSCs) and as CD11b^+^Ly6C^lo^Ly6G^+^ (G-MDSC) ([@B11]). However, several other cell surface markers are introduced such as F4/80, CD124 (IL-4Rα), CD115 (M-CSF-1R), and CD80 (B7.1), which are used for identification of MDSCs subsets and to distinguish MDSCs from neutrophils and monocytes ([@B2], [@B12]). In cancer, the frequency of G-MDSCs in the peripheral lymphoid organs is higher than M-MDSCs. In contrast, MDSCs in tumor sites are mainly M-MDSCs ([@B13], [@B14]). MDSCs are generated in the bone marrow from myeloid progenitor cells and then traffic through the circulatory system into solid tumors. The accumulation of MDSCs in TME mainly depends on two groups of signals. The first group include factors that are mainly secreted by tumor cells, such as stem cell factor (SCF), granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), vascular endothelial growth factor (VEGF), macrophage colony-stimulating factor (M-CSF). These factors stimulate myelopoiesis and promote the expansion of MDSCs in lymphoid organs and TME by activating the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathways. In particular, the transcriptional factors/regulators STAT3, STAT5, IRF8, C/EBPβ, NOTCH play a major role in this process. The second kind of signals includes inflammatory cytokines and chemokines, produced mostly by the tumor stroma, such as IFN-γ, IL-4, IL-6, IL-1β, and CXCL1, which are responsible of inducing the suppressive activity of MDSCs via NF-κB, STAT1, and STAT6 ([@B10], [@B15]). Studies focusing on the role of MDSCs in cancer progression showed that the main activity of these cells is to suppress immunity by perturbing both innate and adaptive immune responses. In tumors, MDSCs have been demonstrated to inhibit cytotoxic T cells proliferation and activation leading to the failure of the anti-tumor immune response, promotion of cancer progression and chemoresistance ([@B16]). The main mechanisms implicated in MDSCs-mediated immune suppression include: (i) deprivation of T cells from essential amino acids; (ii) decreased expression of l-selectin by T cells; (iii) induction of oxidative stress; (iv) induction of immunosuppressive cells like regulatory T (T-regs) and T helper (Th) 17 cells ([@B16], [@B17]). Although the role of MDSCs as potent inducers of T-regs has been widely described in different types of cancer, recent findings also demonstrate that T-regs control MDSCs differentiation and function through different molecules such as transforming growth factor (TGF)-β and the programmed death ligand 1 (B7-H1) ([@B18], [@B19]). However, more research is needed to better dissecting the cross-talk between MDSCs and T-regs in the TME. In addition to suppression of immune surveillance, MDSCs can also directly promote tumor progression and metastasis through non-immunological functions by affecting the remodeling of the TME and tumor angiogenesis via production of VEGF, bFGF, Bv8, and matrix metalloproteinase (MMP)-9 ([@B20]). The main factors implicated in MDSC-mediated immune suppression include arginase 1 (ARG1), inducible nitric oxide synthase (iNOS), TGF-β, IL-10, cyclooxigenase-2 (COX-2), indoleamine 2,3-dioxygenase (IDO) and many others. M-MDSCs and G-MDSCs can utilize different mechanisms to suppress immune response. M-MDSCs express high levels of ARG1 and of iNOS, thus, they suppress T-cell responses, both in antigen-specific and non-specific manners, trough high production of nitric oxide (NO) in the TME. On the other hand, G-MDSCs are capable of suppressing immune responses primarily in an antigen-specific manner and they act mostly through production of high levels of reactive oxygen species (ROS) ([@B14], [@B21]). Several evidences suggest that on a per cell basis M-MDSC are more potent than G-MDSC ([@B13]). In contrast to murine models, the phenotype of MDSCs in humans is not as well-defined. Tipically, human tumor infiltrating MDSCs express the markers CD33 common to cells of myeloid lineage, but lack the expression of the maturation myeloid marker HLA-DR. Analogously to the murine MDSCs, human MDSCs are broadly classified into two different subsets, monocytic and granulocytic, based on the expression of the monocyte differentiation antigen CD14 and the mature monocyte marker CD15. Thus, human M-MDSCs are mostly CD33^+^CD11b^+^CD14^+^HLA-DR^−/low^ whereas human G-MDSCs are CD33^+^CD11b^+^HLA-DR^−/low^CD14^−^CD15^+^. However, the gating strategies used to identify MDSCs populations can vary among researcher. G-MDSCs and neutrophils share similar phenotype; however, they have different density. Recently, identified lectin-type oxidized LDL receptor 1 (LOX-1) allows for better distinction between human neutrophils and G-MDSC. Immune suppressive LOX-1^+^ cells represent 4--15% of all neutrophils in blood of cancer patients and up to 40% in tumor tissues, whereas in healthy individuals, these cells represent \<1% ([@B22]). Conversely, human M-MDSC can be easily separated from monocytes based on the expression of MHC class II molecules which is expressed only on monocytes (HLA-DR^+^) ([@B23]). In addition to the granulocytic and monocytic subtypes, a third small population of putative MDSCs that includes cells with colony-forming activity and promyelocytic appearance was described in humans. These cells, termed immature or early-stage MDSCs (e-MDSCs), have the phenotype CD33^+^CD11b^+^HLA-DR^−^CD14^−^CD15^−^ cells ([@B11], [@B24]). Human M-MDSCs and G-MDSCs, like murine MDSCs, have been shown to exhibit distinct functional attributes. In particular, G-MDSCs primarily use ROS as the mechanism of immune suppression whereas M-MDSCs show up-regulation of iNOS, ARG1, and an array of immunosuppressive cytokines ([@B17]). In recent years, the clinical role of MDSCs has emerged. Numerous studies have reported the expansion of MDSCs in various human cancers including breast, colon, lung, pancreatic, renal, esophageal, and melanomas ([@B24]--[@B26]). Moreover, the frequency of MDSCs have also been negatively correlated with the response to immunotherapy ([@B27]). Therefore, targeting MDSCs in cancer patients may be a viable therapeutic approach to reverse immune escape and to maximize immune based treatments.

However, an important issue in this viewpoint is the great heterogeneity of these cells, which make the identification and isolation of human MDSCs subsets very challenging. Several data found a significant diversity in the MDSCs subsets in different human cancers. Moreover, the frequency and the mechanisms of action of each MDSCs subset seems to be influenced by the cancer type ([@B26]). Thus, the precise identification of cell surface markers and the exact definition of human MDSCs in different types of malignancies can be useful to improve the efficacy of immunotherapeutic interventions and cancer treatment. In this review, we summarize the phenotype and the biological function of MDSCs populations expanded within different tumor contexts which have showed the strongest negative association with MDSCs, as well as discuss their clinical relevance for cancer diagnosis and therapy.

Main Strategies to Therapeutically Target MDSCs in Cancer {#s2}
=========================================================

Inhibition of MDSCs in cancer therapy has proven to be a potentially promising and well-tolerated treatment. Increasing numbers of pre-clinical studies and clinical trials have been performed over the past years in order to evaluate the safety and the efficacy of MDSCs inhibition, alone or in combination with other therapy (radiotherapy, chemotherapy, surgery or immunotherapy) in cancers. Currently, different therapeutic strategies aimed at eliminating MDSCs and/or abrogating their pro-tumor activities are being investigated. These approaches include (1) depletion of MDSCs; (2) inhibition of MDSCs recruitment to the tumor site; (3) inhibition of MDSC\'s suppressive activity; (4) promoting MDSCs differentiation ([Figure 1](#F1){ref-type="fig"}).
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In mouse models, depletion of MDSCs has been generally accomplished by the use of antibodies that target the surface markers Gr-1 or Ly6G ([@B28]). More recently, novel approaches have been developed to more preferentially target and deplete MDSCs. For example, "peptibodies" consisting of S100A9-derived peptides conjugated to antibody Fc fragments have shown potential in eliminating MDSCs in mouse models without targeting other proinflammatory immune cells ([@B29]). In addition, induction of Fas-FasL mediated apoptosis of MDSCs have been resulted effective in suppressing tumor growth and restoring T cells immune response in different murine tumor models ([@B30]--[@B32]). Similarly, targeting the TNF-related apoptosis-induced ligand (TRAIL) receptor could be a potent and selective method for MDSCs depletion ([@B33]). Some chemotherapeutics such as gemcitabine, 5-fluorouracil, paclitaxel, and doxorubicin were shown to selectively eliminate MDSCs in the spleen, blood, and tumor beds in several mouse tumor models resulting in the enhancement of the function of immune effector cells ([@B34]--[@B38]). These findings reinforce the concept that depleting MDSCs has great therapeutic promise. In cancer patients, "conventional" therapies including surgical resection ([@B39]), radiotherapy ([@B40]) or chemotherapy with gemcitabine or 5-fluorouracil, showed a decrease of MDSCs leading to the immune recovery and tumor regression ([@B35], [@B36]). However, MDSC numbers and/or function have been assessed in few chemotherapy clinical trials and have shown mixed results.

Intensive investigations have been performed to reduce MDSCs trafficking to peripheral lymph nodes and tumor sites. Chemokine receptors are a key driving force for the migration of MDSCs and blocking the interactions with their ligands is a rational approach to inhibit MDSCs accumulation in the TME ([@B41]). In particular, therapeutic blockade of CCL2-CCR2 interaction by using CCL2 neutralizing antibodies or CCR2 antagonist has demonstrated promising antitumor efficacies in several preclinical cancer models ([@B42]--[@B44]). However, in a phase II clinical trial, was reported that carlumab (anti-CCL2 mAb) in patients with metastatic castration-resistant prostate cancer, induced a rapid rebound of the circulating concentration of free CCL2 to value higher than the pretreatment serum levels ([@B45]). The CCR5--CCL5 axis has also a critical role in tumor progression since it supports tumor invasion and migration of MDSCs to the tumor site ([@B46]). Indeed, by targeting the CCR5-CCL5 interaction, tumor growth and invasiveness were suppressed in colorectal, prostate, breast cancer and melanoma ([@B47]--[@B50]). Another well-characterized target to reduce MDSCs trafficking is the colony-stimulating factor 1 receptor (CSF1R) whose expression is restricted to monocytes and macrophages. Various inhibitors against CSF1R (such as IMC-CS4, GW2580, PLX3397, AMG820, and emactuzumab) have shown promising antitumor efficacies by inhibiting the survival of M-MDSCs and tumor associated macrophages (TAMs) and are being tested in combination with chemotherapy or immunotherapies in cancer patients ([@B51]). The following MDSCs inhibitors have been evaluated in clinical trials ([@B52]): Reparixin and AZD5069 (CXCR2 antagonists), respectively, in phase II for breast cancer and in phase Ib/II for advanced solid tumors and metastatic squamous cell carcinoma; Plexidartinib (CSF-1R inhibitor) in phase II for recurrent glioblastoma; Maraviroc (CCR5 antagonist) in phase I for metastatic colorectal cancer. The expansion and recruitment of MDSCs to the tumor sites is also mediated by MMP9. It has been shown that administration of amino-bisphosphonates drugs can prevent MMPs from undergoing prenylation, a post-translational modification that is essential for their function. As a result of reduced MMP9 prenylation, cleavage of the tyrosine kinase c-Kit is diminished, causing reduced mobilization of MDSCs ([@B53]). Amino-bisphosphonates have shown a good safety and tolerance and seem to exert therapeutic effects, making them promising candidates to target MDSCs ([@B54]--[@B56]). The inhibition of VEGF receptor signaling also leads to a reduction of MDSCs infiltration ([@B57]). Indeed, the tyrosine kinase inhibitor (TKI) sunitinib was reported to decrease the number of circulating MDSCs in renal cell carcinoma patients via blockade of VEGF and c-KIT signaling ([@B58]). Interestingly, sunitinib treatment resulted also in a significant reduction of STAT3 activation and ARG1 expression in M-MDSCs that was accompanied with an elevated activity and proliferation of CD8^+^ T cells ([@B59]).

Blockade of MDSCs immunosuppressive mechanisms represents the major therapeutic approach to re-establishing T-cells activity and immunotherapy success. MDSCs can be functionally inactivated by targeting their suppressive machinery. For example, disruption of the COX-2/prostaglandin E2 (PGE2) signaling has been successful in repressing MDSC-associated suppressive factors such as ARG1 expression and ROS production, and improving T-cells frequency and immune response ([@B60], [@B61]). Phosphodiesterase-5 (PDE-5) inhibitors are also able to inhibit MDSCs functions by the downregulation of iNOS and ARG1 expression and activities. In preclinical mouse models, administration of PDE-5 inhibitors, such as sildenafil and tadalafil, has been demonstrated to reactivate antitumor immunity through T-cells and natural killer (NK) cells and to prolong survival of tumor-bearing mice ([@B62]--[@B64]). Recent clinical trials with PDE-5 inhibitors have also shown enhanced intra-tumor T-cells activity and improved patients\' outcome in head and neck squamous cell carcinoma (HNSCC) and metastatic melanoma ([@B65]--[@B67]). Blocking the immunosuppressive function of MDSCs can also be achieved by targeting phosphatidylinositol 3-kinase (PI3K). Knockout of PI3K was found to reduce the accumulation of G-MDSCs in tumor-bearing mice, breaking immune tolerance to cancer ([@B68]). Anti-inflammatory triterpenoids, have been demonstrate to reduce intracellular ROS production by MDSCs by upregulating the nuclear factor erythroid 2-related factor 2 (Nrf2) which plays an important role in the cellular protection against free radical damage ([@B69]). Moreover, synthetic triterpenoids, such as CCDO-IM and CCDO-Me, have shown promising anticancer results in phase I clinical trials ([@B69], [@B70]). Administration of ATRA, a vitamin A derivative binding to the retinoid receptor, also led to the downregulation of ROS production in MDSCs by activating the extracellular-signal regulated kinase (ERK)1/2 pathway ([@B71]). The selective class I histone deacetylase (HDAC) inhibitor entinostat has been reported to have an inhibitory effect on MDSCs immunosuppressive functions in several preclinical tumor models ([@B72]--[@B74]). Indeed, analysis of MDSCs response to entinostat revealed significantly reduced ARG1, iNOS, and COX-2 levels in both M- and G-MDSCs subsets. Interestingly, the combination of entinostat with immune checkpoint inhibitors resulted in prolonged survival and delayed tumor growth along with an increase of CD8^+^ T effector cells in tumor-bearing mice ([@B73], [@B74]). Clinical trials involving entinostat are currently underway ([@B52]). Recently, the inactivation of class II HDAC (HDAC6) with ricolinostat was found to further increase the inhibitory effect of entinostat on the MDSCs suppressive activity and on tumor progression ([@B75]). STAT3 is another promising target to reduce MDSCs immunosuppressive functions. Various approaches for STAT3 inhibition, such as inhibiting the ([@B1]) SH2 domain or dimerization, ([@B2]) upstream TKIs (e.g., JAK and Src inhibitors), ([@B3]) antisense oligonucleotides, and ([@B4]) peptide mimetics of physiological negative modulators of STAT3, have been tested in pre-clinical model and in clinical trials. However, their clinical use in advanced solid tumors have revealed limited efficacy or excessive toxicities ([@B76]). Recently, the antisense oligonucleotide STAT3 inhibitor, AZD9150, has been tested in phase I/Ib clinical trials for the treatment of diffuse large B-cell lymphoma. Systemic administration of AZD9150 in patients showed a positive immunomodulatory effect, with a marked decrease in G-MDSCs in the peripheral blood, and a meaningful antitumor activity. Trials to combine this agent with checkpoint-targeting immunotherapies are in progress ([@B77]).

Finally, another therapeutic approach used for targeting MDSCs is aimed to induce MDSCs differentiation, converting them into mature non-suppressive cells. One promising therapeutic appears to be ATRA which was reported to induce the rapid differentiation of MDSCs into mature myeloid cells, such as macrophages and DCs, and to improve T-cells response in cancer patients ([@B78], [@B79]). The mechanism of ATRA-induced differentiation of MDSCs involves specific up-regulation of glutathione synthase and neutralization of high ROS production in these cells ([@B80]). Several studies indicate that vitamin D3 is another agent that can promote myeloid cells maturation and reduce the number of MDSCs in cancer patient. In particular, vitamin D3 administration in HNSCC patients increased levels of IL-12, IFN-γ, and improved T-cells blastogenesis ([@B81]). Transcription factors instrumental for normal myeloid cells development, differentiation and function can also be a target to reducing aberrant myelopoiesis. In particular, the interferon regulatory factor (IRF)-8 is a "master regulator" of normal myelopoiesis, indispensable for producing monocytes, DCs and neutrophils from myeloid progenitors ([@B82]). Thus, enforced expression of IRF-8, either directly or indirectly, may facilitate myeloid differentiation and improves immunotherapy efficacy ([@B83]). Further, it has been hypothesized that tumor-induced IRF8 downregulation occurred through a STAT3-dependent interaction. Indeed, STAT3 inhibition can induce MDSCs differentiation into immunogenic DCs or macrophages ([@B84], [@B85]).

MDSCs in Breast Cancer {#s3}
======================

Breast cancer (BC) is the most commonly occurring cancer and the leading cause of cancer-related deaths in females worldwide ([@B86]). Clinically, BC is a heterogeneous disease. Analyses of gene-expression profiling have identified three main groups of BC based on estrogenic receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2/neu) expression ([@B87]). This classification is critical for guiding treatments, which mainly include surgery (mastectomy or lumpectomy), radiotherapy, anthracycline-based chemotherapy or hormonal therapies with anti-HER-2 monoclonal antibodies (mAb), i.e., trastuzumab, pertuzumab, and TDM1 ([@B88]). Immunotherapy is not yet considered a routine form of treatment for BC patients. However, a recent pooled analysis of 1,954 breast tumor demonstrated that some BC, based on their different immunogenic sensitivity, can be distinguished into two discernible subtypes termed *immune benefit-enabled* and *immune benefit-disabled* which showed significant differences in distant metastasis-free survival ([@B89]). A better understanding of the factors that regulate BC immunogenicity will contribute to create more effective and personalized therapeutic strategies that target specific immunogenic subtypes. In particular, BC weak immunogenicity derive from mechanisms that diminish immune recognition and promote strong immunosuppression. Infiltration of immunosuppressive cells like T-regs, MDSCs or TAMs in the TME has been demonstrated to be the major mechanism of tumor escape from the immune system and the main cause in the reduction of the efficacy of immunotherapy ([@B90]). Indeed, circulating MDSCs in peripheral blood of BC patients have been shown to be elevated in all stages of the disease and to be positively correlated with clinical cancer stage and extensive metastatic tumor burden ([@B91], [@B92]). Conversely, tumors showing greater infiltration of about 50--60% of tumor-associated effector cells, such as cytotoxic T cells, memory T cells, NK cells, tend to be more immunogenic and more sensitive to chemotherapy. Thus, their presence has been associated with the suppression of metastatic recurrence resulting in a relatively good prognostic outcome ([@B93]--[@B96]). Most of the research on MDSCs in the TME has been performed in murine models, which have provided the first evidence that MDSCs are involved in the development and progression of BC. Thus, eliminating MDSCs can result in increased immune-mediated anti-tumor responses and decreased tumor-burden ([@B97]--[@B101]). Nevertheless, also in human it has been showed a direct correlation between MDSCs levels in the peripheral blood of BC patients, disease malignancy and poor prognosis. In one of the earliest study by Diaz-Montero et al. ([@B91]), the percentage and the absolute number of circulating MDSCs were significantly increased in cancer patients compared to normal volunteers. A population of MDSCs, defined as Lin^−/Lo^ HLA-DR^−^CD33^+^CD11b^+^, was detected in fresh whole blood from 106 BC patients. In these patients, it was found that both percentage and absolute number of circulating MDSCs were associated with the clinical cancer stage. Significant differences were observed in mean MDSCs between patients with early stages I/II cancer (1.96%) stage III (2.46%) and advanced stage IV (3.77%). Overall, stage IV patients with widely metastatic disease had the highest percent (4.37%). In that report, it has been also observed that MDSCs levels in the peripheral blood corresponded to circulating tumor cells levels, which are another emerging prognostic marker. Similarly, Solito et al. ([@B102]) also identified MDSCs (Lin^−/Lo^ HLA-DR^−^CD33^+^CD11b^+^) in 25 stage IV BC patients. They showed that subjects with higher circulating MDSCs \> 3.17% (median) at baseline had a poorer overall survival (OS) than patients with circulating MDSCs ≤ 3.17%, with median OS times of 5.5 and 19.32 months, respectively. Interestingly, Yu et al. identified a unique population of MDSCs in BC with the phenotype CD45^+^CD33^+^CD13^+^CD14^−^CD15^−^. They found that these cells increased both in primary cancer tissues and in peripheral blood. The proportion of this cell population correlated with clinical stage and lymph node metastasis status in BC patients and exerted potent immunosuppressive activity on T cells. Further, they reported that IDO, a rate-limiting enzyme of tryptophan catabolism, was significantly upregulated in tumor-infiltrating MDSCs than in periphery, thereby suggesting a pivotal role in developing and maintaining MDSCs-mediated immunosuppressive functions in tissue ([@B103]). Recent studies also confirmed that tumor progression and invasion paralleled the development of MDSCs. For instance, Gonda et al. ([@B104]) reported that the levels of circulating MDSCs (CD33^+^CD11b^+^CD14^−^) in the peripheral blood were increased in BC patients compared with healthy controls. Moreover, MDSCs levels were considerably higher in preoperative patients and decreased in postoperative patients or following chemotherapy, while they reached again high levels in patients with recurrent disease. They found that, in preoperative patients, MDSCs levels positively correlated with IL-6 production while they negatively correlated with IFN-γ and IL-12 production. IL-12 is known to be a modulator of immune suppression which induces Th1 cells while IL-6 promotes a Th2-dominant status. Thus, the immune suppressive function of MDSCs in BC patients may involve multiple immunological pathways, which impair the Th cell balance promoting a shift from Th1 to Th2 predominance. Additionally, Bergenfelz et al. ([@B92]), reported an expansion of circulating CD14^+^HLA-DR^−/low^ M-MDSCs in patients with locoregional recurrence or metastatic BC, which was correlated with increased metastasis to lymph nodes and visceral organs, suggesting that circulating M-MDSCs could be a potential biomarker for disease progression and a guide to individualize efficient immunomodulatory treatments. Also Safarzadeh et al. ([@B105]) showed that M-MDSCs (HLA-DR^−^CD33^+^CD14^+^) represent a high percentage compared with the G-MDSCs (HLA-DR^−^CD33^+^CD15^+^) subpopulation in BC patients. A recent study found that cells with the M-MDSCs phenotype CD14^+^HLA-DR^−/low^ are present at significantly higher frequencies in early-stage BC patients (40 patients with clinical stages I/II), suggesting that M-MDSCs mostly participate to the development of BC by protecting tumor cells from immune attack. In particular, one of the suppressive mechanisms proposed by the authors for M-MDSCs-mediated immunosuppression is represented by ROS ([@B106]). Conversely, Toor et al. ([@B107]) found that BC patients had significant elevated levels of granulocytic CD33^+^ CD11b^+^HLA-DR^−/low^CD15^+^ MDSCs in the TME vs. surrounding healthy tissue whereas no significant differences were observed in their peripheral blood compared to healthy individuals. However, a weakness of this study may be the small number of patients included (23 patients). In BC, after differentiation and recruitment, MDSCs suppress T cells via several pathways including the ARG1, ROS, RNS, and NO pathways ([@B108]). Indeed, nitration/nitrosylation of T cell receptors (TCRs) and CD8 molecules on the surface of T cells induces T cell tolerance ([@B109]). The JAK/STAT pathway is also important in regulating the various functions of MDSCs. Indeed, the transcription factor STAT-3 modulates the expression of target genes involved in various proinflammatory functions. Among them, STAT-3 promotes IDO expression. As mentioned before, IDO act as a major immune regulator inhibiting immune surveillance and promoting immune tolerance by suppressing TCR-mediated activation of T cells, as well as inducing amplification of T-regs ([@B110], [@B111]). Besides their canonical immunosuppressive functions, MDSCs have also direct effects on BC cells contributing to invasiveness and metastasis through the activation of the intracellular phosphatase and tensin homolog (PTEN)/Akt pathway. Upregulation of Akt in MDSCs results in increased expression of MMPs, including MMP2, MMP13, and MMP14, in BC cells which in turn promote invasion and metastasis ([@B108]). Moreover, MDSCs can act as osteoclast progenitors promoting BC metastasis to the bone. Through NO signaling and cross talk with BC cells, MDSCs can differentiate into osteoclasts in the bone microenvironment to exacerbate osteolysis in metastasizing BC which represent important issue for BC patients, causing high morbidity and mortality ([@B98]). In summary, these studies further strengthen the observations that MDSCs numbers increase in patients with BC as compared to healthy people, suggesting that targeting MDSCs may significantly improve the effect of immunotherapy protocols in patients with BC. In preclinical studies it has been demonstrates that CCR5 antagonists inhibited the metastatic potential of basal BC and reduced tumor growth ([@B49]). CSF-1R inhibition and CXCR2 antagonism has also been used in combination to reduce TAMs and G-MDSCs populations and improve anti PD-1 efficacy ([@B51], [@B112]). Further, the HDAC inhibitor, entinostat, in combination with the checkpoint inhibitors anti--PD-1 and anti--CTLA-4, led to a significant suppression of G-MDSCs in the TME and significantly improved tumor-free survival in HER2/neu transgenic BC mouse model ([@B74]). Combination of entinostat with nivolumab and ipilimumab is, currently, under evaluation in a phase I trial in patients with invasive and metastatic BC (NCT02453620). Other clinical studies aimed to investigate the effect of MDSCs inhibitors in combination with immunotherapy are ongoing.

MDSCs in Colorectal Cancer {#s4}
==========================

Colorectal cancer (CRC) is the third most common cancer and the second cause of cancer deaths worldwide ([@B86]). Only 5--6% of CRC cases involve inherited genetic alterations while environmental factors, lifestyle (such as physical inactivity, smoking, alcohol consumption and obesity) and gut microbiota are responsible of \~90% of CRC occurrence ([@B113]). The current approaches to treat metastatic CRC (mCRC) involve multimodal therapy based on chemotherapy (including the combination of cytotoxic drugs) or targeted agents (such as bevacizumab, cetuximab, and panitumumab) ([@B114]). In the last few years, immunotherapy, which typically rely on the activation of T cells in the TME, has been considered for mCRC patients ([@B115]). Checkpoint inhibitors such as antibodies directed against cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death protein (PD-1)/PD-1 ligand (PD-L1) resulted ineffective to produce durable clinical responses due to tumor-mediated immune evasion and resistance, caused by the presence, into the TME, of immunosuppressive cells like MDSCs ([@B116]). In CRC, MDSCs are widely considered the link between chronic inflammation and cancer. Indeed, patients with inflammatory bowel disease, such as ulcerative colitis, show an increased risk of developing CRC ([@B117]). Evidences from studies in mouse models of colitis-associated cancer (CAC) indicate that chronic inflammation can drive tumor initiation and progression by enhancing MDSCs accumulation and immune suppression ([@B118], [@B119]). Accumulating data also support a role for the microbiota in CRC carcinogenesis ([@B120]). Recent studies have shown that symbiotic bacteria like *Fusobacterium nucleatum* and *Helicobacter hepaticus* can exacerbate the development of cancer by inducing MDSCs expansion in the inflamed colon of mice ([@B121], [@B122]). Although both MDSCs subtypes have been found increased in several colon cancer mouse models, the expansion of G-MDSCs resulted much greater compared to M-MDSCs ([@B118], [@B119], [@B122], [@B123]). In CRC patients, at first, MDSCs were identified generally as CD33^+^HLA-DR^−^ ([@B124], [@B125]). Both circulating and tumor-infiltrating MDSCs have been found significantly expanded in patients with various stage of CRC compared with healthy donors. Interestingly, their frequencies were shown to increase with tumor stage and with the presence of nodal and/or distant metastasis, indicating a correlation with clinical cancer stage. These MDSCs displayed characteristics of immature myeloid cells expressing no level of the lineage markers CD3, CD14, CD19, and CD56. Notably, they showed up-regulation of CD18/CD11b expression, which is critical for cell adhesion and migration, suggesting the involvement of MDSCs in CRC tumor development ([@B124]). Further, Zhang et al. ([@B125]) demonstrated that Lin^−/low^HLA-DR^−^CD33^+^CD11b^+^ MDSCs had immunosuppressive effect on T cells and expressed high level of the ectonucleotidase molecule CD39, which plays a key role in mediating the suppressive activity of MDSCs on T cells, by converting immunostimulatory ATP into immunosuppressive adenosine. A better phenotypical characterization of MDSCs in CRC patients was originally reported by OuYang et al. ([@B126]). They observed an increased proportion of CD33^+^CD11b^+^HLA-DR^−^ MDSCs in peripheral blood and tumor tissues which correlated with advanced disease stages and tumor lymph node metastases. In particular, this population consisted for the major part of a M-MDSCs subset (CD33^+^CD11b^+^HLA-DR^−^CD14^+^CD15^−^) and an atypical G-MDSCs subset, with a moderate expression of the granulocyte-monocyte progenitor cell markers CD117 and a weak expression of the granulocytic marker CD15. These MDSCs populations were found to suppress both CD8^+^ and CD4^+^ T cells proliferation through the oxidative metabolism, including the generation of NO and ROS, as demonstrated by the high expression levels of the immune mediators ARG1, iNOS, and NOX2. Conversely, Toor et al. ([@B127]) identified CD33^+^CD11b^+^HLA-DR^−/low^CD15^+^ G-MDSCs as key players among others in CRC progression. They found a significant expansion of G-MDSCs in both circulation and in tumor tissues of 21 CRC patients with different tumor stages. In particular, circulating G-MDSCs were significantly elevated in CRC patients with regional and distant metastases and exerted their immunosuppressive functions trough the activation of ARG1. Several factors have been implicated in the regulation of the accumulation and the suppressive functions of MDSCs in CRC. IL-17 appears one of the main driving chemoattractant forces, especially for G-MDSCs, within the TME ([@B128]). In murine tumor models, IL-17 promotes MDSCs tumor infiltration, in a CXCL5/CXCR2-dependent manner, and enhances the immunosuppressive activity of MDSCs ([@B129]). Chun et al. ([@B119]) postulated that CCL2 acts as a neoplastic regulator of MDSCs, contributing to their intratumoral accumulation and to G-MDSC-mediated suppression of CD4^+^ and CD8^+^ T cells via STAT3-mediated pathway. Indeed, increased CCL2 in patients with early-stage colon cancer (colitis-associated CRC, adenocarcinomas, and adenomas) influences carcinogenesis inducing MDSCs. Thus, CCL2 neutralization may afford therapeutic opportunities to decreased MDSC accumulation and function. Recent data indicate that Yes-associated protein 1 (YAP1) and PTEN can mediate CRC tumorigenesis through the induction of MDSCs in the TME. In fact, Yang et al., describe that up-regulation of YAP1 in the tumor promoted MDSCs expansion through suppressing PTEN expression and subsequently inducing the secretion of GM-CSF ([@B130]). Further, inhibition of Kit has been demonstrated to enhance the antitumor activity of immune checkpoint inhibitors (anti--CTLA-4 and anti--PD-1) by selectively reducing the immunosuppressive M-MDSCs population in Colon26 mouse tumor model ([@B131]). The humanized anti-Kit mAb KTN0158 has also been evaluated in clinical trials for patients with Kit positive advanced solid tumors (NCT02642016). Notably, the inhibition of STAT3 signaling pathway with nifuroxazide inhibited lung and abdomen metastasis in mice and reduced the number of MDSCs in the blood, spleens and tumors, accompanied by the increased infiltration of CD8^+^ T cells ([@B132]). Targeting TRAIL-R2 with the agonist antibody DS-8273a was applied in a phase I clinical trial in patients with advanced cancers, including CRC patients, in combination with nivolumab and caused selective depletion of MDSCs without affecting mature myeloid or lymphoid cells ([@B133]). Thus, a better identification of the molecular mechanism driving MDSCs expansion in CRC may guide the future development of new therapeutic strategies for CRC patients based on targeting MDSCs.

MDSCs in Melanoma {#s5}
=================

Melanoma is the most aggressive and fatal form of skin cancer with a high mortality rate. Primary melanoma is usually curable with surgery when diagnosticated in early stages ([@B134]). Nonetheless, melanoma is characterized by a lively progression that is correlated to rapid metastasis development to regional lymph nodes and distant organs as well as therapy resistance by reducing the patients median survival to \<1 year ([@B135]). In fact, despite the recent introduction of encouraging immunotherapies such as ipilimumab and pembrolizumab, that target CTLA-4 and PD-1 respectively, the majority of patients experience resistance and tumor progression ([@B136]). This critical condition is partially due to the immunosuppressive mechanisms established within the TME mediated by immunoregulatory cells including T-regs and MDSCs that contributes to immune evasion ([@B137]). In particular, multiple reports have highlighted the role of MDSCs as one of the most important restrictions preventing efficient melanoma treatment ([@B116]). Several reports indicated an increased frequency of both M-MDSCs and G-MDSCs in melanoma patients ([@B138]--[@B141]). For instance, Jordan et al. demonstrated that the frequency of both M-MDSCs (Lin^−^CD11b^+^HLA-DR^−/low^CD33^+^CD14^+^) and G-MDSCs (Lin^−^CD11b^+^HLA-DR^−/low^CD33^+^CD14^−^) subsets was significantly increased in the peripheral blood of stage IV melanoma patients and was associated with disease progression and decreased OS ([@B142]). Similarly, Filipazzi et al. reported an expansion of CD14^+^CD11b^+^HLA-DR^−/low^ M-MDSCs in fresh whole blood from 70 advanced melanoma patients suggesting an inverse correlation with immune responses to cancer vaccine ([@B138]). Additionally, Weide et al. also reported that circulating CD14^+^CD11b^+^HLA-DR^low^ M-MDSCs were inversely correlated to both OS and the presence of functional antigen-specific T cells in patients with advanced melanoma ([@B140]). Conversely, more recently Stanojevic et al., demonstrated that HLA-DR^−/low^CD11b^+^CD33^low^Lin^−^CD14^−^CD15^+^ G-MDSCs population was significantly higher in different clinical melanoma stages according to both TNM and AJCC classification ([@B143]). Thus, MDSCs abrogation and inhibition, could be the next biggest aims for melanoma treatment ([@B144]). In fact, in the last few years, various preclinical studies have been focused in measuring and targeting MDSCs in melanoma patients, resulting in tumor growth inhibition and survival prolongation ([@B145]). Nevertheless, there are different ongoing clinical trials focused on evaluating the effect of new molecules that target MDSCs in melanoma patients such as ATRA), SX-682 or omaveloxolone in combination with classical immune checkpoint inhibitors ([@B116], [@B144]). ATRA, that has previously demonstrated to induce differentiation of MDSCs into macrophages and DCs in mice, ([@B80]) has been applied in a phase II clinical trial in combination with ipilimumab in melanoma patients. The study demonstrated that this combination improved the clinical outcome by increasing tumor antigen-specific T cell responses and reducing MDSCs frequency as compared to ipilimumab alone ([@B146]). SX-682 is a selective and potent antagonist of CXCR1/2 chemokine receptors that are expressed on both melanoma cells and MDSCs supporting tumor growth, immunosuppression and angiogenesis in response to CXCL1, CXCL2, or CXCL8 ([@B147]--[@B149]). Omaveloxolone (also referred as RTA408), is a semisynthetic oleanane triterpenoid that represses ROS production and NO signaling in MDSCs showing promising preclinical antitumor activity ([@B150]). Both SX-682 and RTA408 have been applied in two different clinical trials in combination, respectively with pembrolizumab (NCT03161431) and ipilimumab or nivolumab (NCT02259231) ([@B116], [@B144], [@B151]). Interestingly, MDSCs enrichment in melanoma patients has been frequently associated to heightened amounts of inflammatory mediators such as IFN-γ, IL-1β, IL-4, IL-13, TNF-α, toll-like receptor (TLR) ligands, and PGE2 that support MDSCs accumulation and activation ([@B152], [@B153]). PGE2 is one of the best-characterized prostaglandins synthesized by COX-2. Recently, we and others reported that COX-2 has a crucial role in melanoma development and progression by affecting patients progression free survival (PFS) ([@B154]--[@B156]). In particular, PGE2 production by MDSCs has been associated to ARG1 overexpression, STAT3 and STAT1 phosphorylation and IL-10, ROS, and NO production that are correlated to MDSCs suppressive activity ([@B157]--[@B160]). Thus, PGE2--dependent activation of MDSCs result to be a potent additional mechanism of tumor immune escape which is driven by COX-2 ([@B161]). Indeed, COX-2 pharmacologic inhibition reverts MDSCs suppressive phenotype by reducing the production of ROS and NO, the expression of ARG1 and restoring the differentiation of bone marrow cells ([@B162], [@B163]). Nevertheless, a better understanding is necessary to figure out which mechanisms PGE2 exploits for triggering MDSCs immunosuppressive effects in malignant melanoma. Recently, a new class of compound defined as hydrogen sulfide donors, has been shown to inhibit both the expansion and the suppressive functions of MDSCs in melanoma-bearing mice ([@B164]). Interesting results have also been achieved in the field of microRNAs (miRNAs) ([@B165]). miRNAs are relevant multifunctional post-transcriptional modulators of gene expression which have been reported to play a key-role in various human cancers including melanoma ([@B166]--[@B171]). Different evidences established an emerging role for miRNAs in the expansion and functional activation of MDSCs during tumor development ([@B165]). For instance, miR-155 has been shown to promote tumor growth by triggering MDSCs ripening, endurance and function through SOCS1 inhibition ([@B172]). More recently, Huber et al., discovered a set of miRNAs that are associated with the phenotypic and functional features of MDSCs in melanoma patients ([@B173]). Most importantly, they reported that higher expression of these miRNAs is correlated to shorter PFS in patients receiving ipilimumab and nivolumab ([@B173]). Finally, miRNAs identification as MDSC regulators, could be an additional and promising strategy to fight and monitor systemic immunosuppression that occur in melanoma patients, mainly driven by MDSCs.

MDSCs in Prostate Cancer {#s6}
========================

Prostate cancer is the most commonly diagnosed cancer in males in the world and is responsible for about 20% of cancer-related deaths ([@B174]). Prostate cancer diagnosis is divided in low, intermediate and high risk according to Gleason patterns, prostate specific antigen (PSA) levels and clinical stage ([@B175]). Surgical or chemical androgen deprivation therapy (ADT) is the first-line treatment once the disease spreads outside the prostate in order to reduce circulating testosterone levels ([@B176], [@B177]). Nevertheless, an important percentage of patients experience resistance and tumor progresses to a more aggressive form referred as castration-resistant prostate cancer (CRPC) after 18--36 months ([@B178], [@B179]). This advanced form of prostate cancer is usually treated with classical chemotherapy regimens including docetaxel and cabazitaxel ([@B179]). Moreover, there are also novel hormone therapies available for CRPC such as abiraterone and enzalutamide ([@B180], [@B181]). In 2010, the U.S. Food and Drug Administration (FDA) approved PROVENGE (sipuleucel-T), the first immunotherapy agent for the treatment of patients with asymptomatic or minimally symptomatic metastatic CRPC. Sipuleucel-T stimulates T-cell immune response against prostate cancer cells by targeting prostatic acid phosphatase (PAP), an antigen that is highly expressed in most prostate cancer cells ([@B182]). Despite these recent advances, treatments only provide scanty survival benefits and most patients develop disease relapse ([@B183]). Investigating on the mechanisms that may drive prostate cancer progression, different data reported that it is surrounded by a complex TME ([@B184], [@B185]). In particular, MDSCs are the most renowned immune cells subset that has been reported to infiltrate the prostate TME ([@B186]--[@B188]). In fact, by evaluating the frequency of MDSCs in the blood of prostate cancer patients the CD14^+^HLA-DR^low^ monocytic subset result to be augmented compared with sex- and age-matched healthy donors, whereas it is decreased after ADT ([@B39], [@B189]). Conversely, Chi et al., reported that circulating CD33^+^CD11b^+^HLA-DR^−^CD14^−^ granulocytic MDSCs represented the major subtype of MDSCs in patients with prostate cancer and their level were significantly elevated compared with both healthy donors and patients with benign prostatic hyperplasia (BPH) ([@B190]). Interestingly, Idorn et al., showed that the levels of CD14^+^HLA-DR^low/−^ M-MDSCs were increased in both untreated and docetaxel-treated CRPC patients and that they were correlated with a shorter median OS, suggesting that MDSCs support prostate cancer progression ([@B191]). Additionally, they also reported a significant positive correlation between MDSCs and T-regs frequency in peripheral blood of CRPC patients denoting a cross-talk between these two immunomodulatory cells ([@B191]). This intricate scenario is orchestrated by different mediators such as cytokines, chemokines and growth factors that contribute to the accumulation of MDSCs in prostate tumors ([@B192]). In particular, elevated levels of IL-6 pro-inflammatory cytokine, have been reported to promote cancer cell growth and significantly correlate with MDSCs expansion ([@B193]--[@B195]). In fact, it has been showed, in mice, that high serum levels of IL-6 were positively associated to MDSCs recruitment ([@B195]). This data has been further reinforced by using IL-6 KO mice in which the inhibition of tumor-produced IL-6 significantly reduced MDSCs recruitment ([@B195]). Similarly, Chi et al. reported that MDSCs frequency was correlate with serum levels of IL-6 and IL-8 in prostate cancer patients ([@B190]). This IL-6-mediated immunosuppressive effect involves different signaling pathways including PI3K/PTEN/AKT pathway which in turn triggers MDSCs recruitment ([@B196], [@B197]). Interestingly, more recently, Calcinotto et al., reported that IL-23 cytokine is another important MDSC-secreted factor that drives CRPC progression in both human and mice by sustaining the growth and the endurance of prostate cancer cells as well as the transcription of androgen dependent genes such as Nkx3-1, Pbsn, and Fkbp5 ([@B186], [@B198]). Moreover, co-administration of anti IL-23 antibody with enzalutamide, reverted resistance to castration in tumor-bearing mice by reducing tumor volume and proliferation ([@B186]). These findings demonstrated that MDSCs are the major players involved in prostate cancer progression and resistance. Thus, immunotherapies focused on the inhibition of either MDSCs recruitment or the inhibition of other mediators that sustain MDSCs immunosuppressive effect (e.g., IL-6 and IL-23) can be a promising therapeutic strategy for prostate cancer patients. Several clinical trials targeting MDSCs in prostate cancer are ongoing ([@B197]). One promising agent is tasquinimod, an oral second-generation quinoline-3-carboxamide derivative ([@B199]). Tasquinimod inhibits S100A9 protein that interacts with the receptor for advanced glycation end products (RAGE) and TLR4, triggering the inflammatory response ([@B200]). S100A9 is also involved in MDSCs recruitment in solid tumors sustaining tumor growth and metastasis development ([@B201]). A phase II clinical trial demonstrated that tasquinimod improved both PFS and OS in prostate cancer patients compared to placebo ([@B202], [@B203]). Nonetheless, in a phase III randomized controlled trial, tasquinimod significantly improved PFS but did not improve OS ([@B204]). However, larger controlled clinical trials are needed to confirm and validate tasquinimod as a standard agent for the treatment of CRPC.

MDSCs in Hepatocellular Carcinoma {#s7}
=================================

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Cirrhosis and liver inflammation are frequently associated with HCC, and inflammation is considered one of the main factors driving hepatocarcinogenesis ([@B205]). HCC is a highly chemotherapy-resistant tumor and the applicability of most cytotoxic drugs is severely limited by the underlying liver cirrhosis. Currently, sorafenib and lenvatinib, oral multi-TKIs with antiangiogenic activity, are the most widely used systemic therapeutic agents which have showed increase in median survival in patients with unresectable HCC, respectively of 12.3 and 13.6 months ([@B206], [@B207]). Recently, other oral multi-TKIs, regorafenib and cabozantinib, have been added as second line systemic therapeutic options in patients with disease progression on sorafenib ([@B208], [@B209]). In the last few years, the interest in immunotherapies for HCC has been growing giving great opportunities for treating HCC with newer and more sophisticated agents ([@B210]). In particular, encouraging results has been obtained with the anti PD-1 mAbs nivolumab and pembrolizumab, which exhibited an objective tumor response of about 20% in HCC patients who had been previously treated with sorafenib ([@B207], [@B211]). Optimizing this response is challenging, especially because of the immune environment on which HCC arises. Although \~25% of HCC show high or moderate levels of lymphocyte infiltration (TILs), within the TME ([@B212]), they often prove insufficient to control tumor growth because the expansion of immunosuppressor cells like MDSCs and Tregs ([@B213]). Indeed, there is a general consensus that various dysfunctions of the immune system contribute to HCC development and progression ([@B214], [@B215]). In the chronic inflammatory milieu present in the liver of HCC patients, myeloid cells infiltrating the tumor can acquire suppressive capability and contribute to immune escape of HCC cells. In the last decade, the clinical importance of MDSCs in HCC patients has been investigated. Several authors have reported elevated level of total MDSCs with the phenotype HLA-DR^−/low^CD11b^+^CD33^+^ in HCC patients compared with healthy controls ([@B216]--[@B218]). In other studies, MDSCs were identified as CD14^+^HLA-DR^−/low^, which are considered to be M-MDSCs. These M-MDSCs were found to be significantly elevated in the peripheral blood or tumor of HCC patients compared with chronic hepatitis patients and healthy controls. Moreover, the frequency of circulating MDSCs, both total and M-MDSCs, was significantly correlated with reduced OS and tumor progression ([@B213], [@B219], [@B220]). Later, Hetta et al. observed that HCV-HCC patients with advanced stage had higher percentage of total MDSCs and M-MDSCs in the peripheral blood compared with those with early-stage HCC and healthy control. The frequency of M-MDSCs subsets was positively correlated with liver related laboratory parameters, especially AFP and ALT, which reflects a hepatic insult whereas, was inversely related to the frequency of CD4^+^, CD8^+^ T, and CD19^+^ B cells. Moreover, patients with chronic liver disease had a significantly higher percentage of MDSCs suggesting that an increased level of MDSCs may contribute to the progression from chronic hepatitis to HCC ([@B221]). In a recent publication, an extensive study on 183 HCC patients showed the prognostic value of CD14^+^HLA-DR^−/low^ M-MDSCs for predicting early recurrence (within 2 years) in patients undergoing curative resection. In particular, the authors observed a significant positive correlation between the frequency of MDSCs and the systemic immune-inflammation index (SII), which is a powerful prognostic indicator of poor outcome in HCC patients after resection. Thus, HCC patients with high MDSCs level and high SII level had significantly shorter time to recurrence (TTR) and OS than those with low MDSC level and low SII level ([@B219]). However, due the limitations of this study, such as relatively small cohort size, short follow-up time, and data from a single study center, the prognostic significance of MDSCs requires further validation. Clinical studies of MDSCs in HCC have mainly focused on analyzing M-MDSCs. Recently, Nan et al. employed a novel marker, LOX-1, to analyze G-MDSCs in HCC patients and determined that LOX-1^+^CD15^+^ cells were significantly increased both in the peripheral blood and in tumor tissue of patients compared with healthy controls and were positively related to OS. Moreover, LOX-1^+^CD15^+^ MDSCs suppressed T-cell proliferation through the ROS and ARG1 pathway and reduced interferon IFN-γ production ([@B222]). Mechanistically, also M-MDSCs isolated from the peripheral blood of HCC patients have been proven to be immunosuppressive by inducing CD4^+^CD25^+^Foxp3^+^ regulatory T cells and inhibiting autologous NK cells, as well as they shown to have high ARG1 activity ([@B213], [@B223]). Nonetheless, Shen and colleagues, described an immature subset of Lin^−^ HLA-DR^−^CD33^+^ MDSCs in the peripheral blood of patients with primary HCC and their frequency was found to be positively correlated with tumor stage and splenomegaly. In the same way, the immature MDSCs were able to inhibit tumor-specific T-cell responses and IFN-γ secretion through a suppressive mechanism involving ARG1 and iNOS enzymes ([@B224]). Regarding the mechanism of MDSCs expansion, it was found that the serum levels of suppressive cytokines like IL-10 and IL-13 as well as of tumor-promoting factors like G-CSF, VEGF and MMP-13 were significantly increased in patients with high frequency of MDSCs ([@B220], [@B224]). Indeed, these cytokines, that trigger JAK-STAT signaling pathways are considered to be the main regulators of the activation of MDSCs, which leads to stimulation of myelopoiesis and inhibition of myeloid-cells differentiation ([@B225]).

Most published studies on human MDSCs in HCC patients have been done using blood samples. Thus, in order to better understand the complex immunobiology of MDSC in HCC, different murine HCC models have been employed: carcinogen-induced, spontaneous and transplantable HCC. Although all tumor bearing mice demonstrated elevated MDSCs level (identified as CD11b^+^Gr-1^+^ cells), subtle differences in frequency, location and function of MDSCs were found among the murine models ([@B226]). Pre-clinical models of HCC have been also used to evaluate the ability of sorafenib to modulate MDSCs. Several studies have reported that sorafenib could enhance the antitumor immunity by reducing MDSCs in tumor-bearing mice ([@B226], [@B227]). On the other hand, targeting MDSCs with anti-Ly6G or anti-IL-6 antibody significantly reduced the frequency of Ly6G^+^ MDSCs in orthotopic liver tumors improving the therapeutic effect of sorafenib ([@B228]). However, Chen et al. ([@B229]) demonstrated that sorafenib increased the intratumoral infiltration of Gr-1^+^ MDSCs through the SDF1α/CXCR4 pathway while reduced the accumulation of Gr-1^+^ myeloid cells in the surrounding fibrotic liver tissue. Differences in these studies might depend on the mouse liver cancer model, the sorafenib dose or the gating strategy used. Further, recent studies have investigated the role of MDSCs in the efficacy of checkpoint inhibitors in mouse HCC models. Chiu et al. found that targeting the enzyme, ectonucleoside triphosphate diphosphohydrolase 2 (ENTPD2), which support the maintenance of MDSCs, enhanced the efficacy of PD-1/CTLA-4 blockade ([@B230]). Likewise, depletion of the cell cycle-related kinase (CCRK) reduced tumor-infiltrating MDSCs and increased intratumor CD8^+^ T cells, thus enhancing the efficacy of PD-L1 inhibitor to eradicate HCC ([@B217]). In addition, an *in vitro* study demonstrated that combination of sorafenib with an anti-CTLA-4 mAb restored the proliferation of CD8^+^ lymphocytes co-cultured with MDSCs ([@B231]). Radiotherapy is commonly used as alternative approaches for HCC patients who may experience serious adverse effects to chemotherapeutics. Interestingly, a decrease in percentages of CD14^+^HLA-DR^low/−^ MDSCs was observed in patients who received curative radiofrequency ablation ([@B220]). Recently, it has been reported that hypofractionated irradiation with high dose per fraction reduced the level of circulating MDSCs in two HCC tumor-bearing mouse models and decreased the expression of MDSC-related stimulatory cytokines: IL-6, G-CSF and RANTES ([@B232]). Collectively, these preclinical studies not only confirmed the roles of MDSCs in tumor formation and progression but also indicated the importance to reduce MDSCs in order to improve the efficacy of therapeutic strategies in HCC. However, these results remain to be confirmed in cancer patients. In this regard, a recent phase I/Ib study (NCT01839604) tested the effect of danvatirsen (AZD9150), a STAT3 oligonucleotide inhibitor, in 39 patients with advanced/metastatic HCC. At the end of the study the results reported that only one patient had a partial response. A phase I/IIa clinical trial is evaluating the outcome of HCC patients, progressing under sorafenib, following the treatment with regorafenib, a multi-TIKs that targets angiogenic (VEGFR1--3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic receptor tyrosine kinases (KIT, RET, and RAF) in combination with nivolumab (NCT04170556).

MDSCs in Lung Cancer {#s8}
====================

Lung cancer is one of the most commonly diagnosed malignancies that is strongly correlated with cigarette smoking and is a leading cause of cancer-related death ([@B233]). Lung cancer is generally divided into two types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Both SCLC and NSCLC are treated with similar chemotherapeutic agents often in combination such as cyclophosphamide, doxorubicin, and vincristine (CAV) or cyclophosphamide, doxorubicin and etoposide (CDE) ([@B234]--[@B236]). In addition, different targeted antibodies and immunomodulators are currently used for the treatment of lung cancer ([@B237], [@B238]). However, a high percentage of patients do not respond or develop resistance to treatment promoting cancer progression ([@B239], [@B240]). MDSCs represent, together with Tregs as well as TAMs, the major immunosuppressive cells that make up the TME in lung cancer patients ([@B241]). For lung cancer, the main body of literature reports increases of monocytic CD33^+^CD11b^+^CD14^+^ MDSCs or granulocytic-like CD33^+^CD11b^+^CD14^−^ MDSCs ([@B242]--[@B245]). For instance, Feng et al., defined MDSCs as CD11b^+^CD14^+^ expressing high levels of the proinflammatory molecule S100A8/A9 whose expression was highly correlated with the ability to suppress T-cells proliferation ([@B244]). Recently, de Goeje et al., showed for the first time that the immunoglobulin-like transcript 3 (ILT3) represent a novel immunosuppressive molecule expressed by defined MDSCs subsets in lung cancer patients. In particular, ILT3 high expression on a specific subset of G-MDSCs, defined as CD11b^+^CD14^−^HLA-DR^−^CD33^+^CD15^+^ILT3^high^, was correlated with reduced survival into NSCLC patients ([@B246]). Interestingly, increased frequency of both M-MDSCs (HLA-DR^−/low^CD11b^+^CD14^+^CD15^−^) and G-MDSCs (HLA-DR^−/low^ CD11b^+^CD14^−^ CD15^+^) has been found not only in the peripheral blood of patients but also in the tumor lesions. Indeed, a strong elevation of both tumor-infiltrating MDSCs subsets compared with the circulating subsets has been showed, confirming that the tumor site is characterized by the strongest immunosuppression. In particular, the frequency of tumor infiltrating and circulating G-MDSCs correlated with tumor progression ([@B247]). Among the different mediators that have been reported to regulate MDSCs suppressive functions, gp91phox, which is correlated to NADPH oxidase enzyme ([@B248]), results to be upregulated in MDSCs of lung cancer patients ([@B242]). The activity of NADPH oxidase enzyme translates into an increase in ROS production which mediates tumor immunosuppression and might thus represent a potential target for therapeutic intervention. Other important mediators involved in cancer immunosuppression are IDO and the adenosine (ADO)-producing enzymes CD39 and CD73 ([@B249]--[@B253]). It has been reported that ADO-producing enzymes are expressed in MDSCs isolated from the peripheral blood of NSCLC patients and favor their immunosuppressive function. Further analysis identified a novel MDSCs subpopulation enriched in CD39 and CD73 in tumor lesions of NSCLC patients defined as Lin^−^CD14^−^CD11b^+^CD39^+^CD73^+^ and Lin^−^CD14^+^CD11b^+^CD39^+^CD73^+^ that were found to be positively correlated to disease progression and were reduced after chemotherapy cycles suggesting them as predictive tools for chemotherapy response ([@B254]). Moreover, the ratio between Treg cells and G-MDSCs may also have an impact on the response to nivolumab treatment, since patients with a high frequency of circulating Tregs and low frequency of G-MDSCs show improved PFS in NSCLC patients ([@B255]). However, more research is needed to better understand the correlation between MDSCs and Tregs in this type of cancer. Given these evidences about the association between MDSCs and anticancer therapies, strategies focusing on the functional targeting of MDSCs are fast approaching clinical realization. For example, depletion of MDSCs increases the frequency and activity of NK and T cell effectors in the tumor and enhance therapeutic vaccination responses ([@B256]). Furthermore, it has been also demonstrated that dopamine receptor D2 (DR2) agonists and histamine type-2 receptor antagonists, such as carbegoline and cimetidine respectively, inhibit the progression of lung cancer in both human and mouse models by affecting at least in part MDSCs proliferation and function ([@B30], [@B257]). Interestingly, different natural compounds, such as resveratrol and curcumin, have been defined as novel synergistic agents for tumor immunotherapy. It has been demonstrated that resveratrol reduces *in vivo* lung cancer development and progression by inducing MDSCs apoptosis and reducing the recruitment of G-MDSCs ([@B258]). Likewise, curcumin reduced the frequency of MDSCs in the tumor and the spleen of tumor-bearing mice that was correlated to the reduction of IL-6 which is known to influence the function of MDSCs ([@B259], [@B260]). Giving the promising data regarding the targeting of MDSCs in mouse lung cancer, several clinical trials are now ongoing in NSCLC patients (NCT02922764; NCT03846310; NCT03801304; NCT04262388).

Conclusion {#s9}
==========

To overcome tumor immune evasion is the new challenge of our era. Cancer immunotherapy has experienced remarkable advances in recent years, and significant improvements have been achieved in the treatment of several solid cancer types (e.g., melanoma, non-small cell lung cancer, bladder cancer). However, for most patients a favorable initial response to treatment changes afterwards, thereby leading to cancer relapse and recurrence. A key factor underlying the limited response to immunotherapies is the existence of multiple mechanisms mediating tumor immune suppression ([@B261]). In this context, MDSCs have been recognized to have a crucial role. Recent studies demonstrated the value of MDSCs in predicting the response to cancer immunotherapies. In particular, a close association of MDSCs level with patient response to the checkpoint inhibitors anti-CTLA4 ([@B262], [@B263]) and anti-PD-1 ([@B264]) has been observed. Moreover, a growing number of studies have demonstrated a significant correlation between circulating MDSCs frequency in cancer patients with tumor stage, metastatic spreading, and course of the disease. Indeed, a recent meta-analyses including 40 studies and 2,721 patients with solid cancer support the existence of an association between higher MDSCs levels and worse OS as well as shorter disease-free survival/progression-free survival/recurrence-free survival. The negative prognostic value of MDSCs was observed for all MDSCs subtypes, most tumor types, and all tumor stages suggesting a potential novel and promising use of MDSCs as prognostic biomarkers and/or therapeutic target ([@B265]). Initial studies monitored MDSCs in cancer patients, analyzed total MDSCs population (G-and M-MDSC together). The diversity of cell surface markers used to identify the main subsets of tumor-derived MDSCs in human is very high, which is in part due to the differences in the factors that are involved in the development and activation of MDSCs. The complexity of the human MDSCs phenotype is summarized in [Table 1](#T1){ref-type="table"}, with the main MDSCs phenotypes expanded in cancer patients and the common immunosuppressive mechanisms. The M-MDSCs subset defined as HLA-DR^−/low^CD14^+^, resulted to be predominant in melanoma, breast cancer and hepatocellular carcinoma. Conversely, in colorectal cancer G-MDSCs defined as HLA-DR^−/low^ CD15^+^ were the most abundant in both circulation and in tumor tissues. In prostate cancer and in lung cancer both G-MDSCs and M-MDSCs subsets were significantly elevated in patients and positively correlated to disease progression. However, despite most of the suppressive mechanisms and phenotype differences reported seemed shared among MDSCs subsets and tumor types, it is necessary to further dissect their role in order to define whether these differences are real or related to some bias from analysis of some markers/mechanisms. Numerous preclinical studies carried out in mouse tumor models, have showed that targeting MDSCs improved the effect of anti-cancer therapies ([@B266]--[@B268]). Although tumor mouse models could be useful for a better understanding of the mechanisms of induction, expansion, trafficking, and function of MDSCs in tumor, and for a rapid screening of anti-MDSCs agents *in vivo*, the translation in human is not so straightforward. First, the identification of human MDSCs phenotype is still challenging, owing the great heterogeneity of MDSCs in different cancers. Second, most human studies focus only on circulating MDSCs while little is known about tumor infiltrating MDSCs. Thus, a better and univocal characterization of the predominant subsets of MDSCs in several types of cancer as well as their further evaluation at the tumor site represent a compelling requirement in order to develop new effective strategies for targeting MDSCs. It is well-known that different subsets of MDSCs could use different mechanisms to suppress T-cells function. Therefore, the identification of the specific immunosuppressive mechanism is also essential to find the proper agent to block it and, consequently, to inhibit their function. Reduction of MDSCs expansion and recruitment to peripheral lymph nodes and tumor sites, inhibition of MDSC\'s suppressive activity and promotion of their differentiation into mature non-suppressive cells are the current therapeutic approaches that are being investigated to target MDSCs ([Figure 1](#F1){ref-type="fig"}). So far, only few agents approved by FDA have been reported to have direct effects on MDSCs accumulation, maturation, and function (e.g., ATRA, Vitamin D, Suitinib, Gemcitabine, Bevacizumab, Tadalafil). However, a wide number of therapies and combination therapies are currently being tested in human clinical trials ([Table 2](#T2){ref-type="table"}) demonstrating an improvement of the patients\' clinical outcome ([@B146], [@B202], [@B203]). In sight of this, further studies are needed to identify or confirm key mechanisms and upstream signals involved in MDSCs generation, expansion and immunosuppressive function in different malignancies. Advances in this field should facilitate rational design of new strategies to target MDSCs in cancer in order to enhance clinical responses to current immunotherapies and improve OS in patients.

###### 

Phenotype and immunosuppressive features of MDSCs subsets in cancer patients.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **MDSCs type**   **Phenotype**                                        **Immunosuppressive features**                    **Tumor**   **Site**   **References**
  ---------------- ---------------------------------------------------- ------------------------------------------------- ----------- ---------- -----------------------------
  T-MDSCs          Lin^−/Lo^ HLA-DR^−^ CD33^+^CD11b^+^                  \-                                                BC          PBMCs      ([@B91], [@B102])

  T-MDSCs          Lin^−/Lo^ HLA-DR^−^ CD33^+^CD11b^+^                  CD39                                              CRC         PBMCs      ([@B125])

  T-MDSCs          Lin^−/Lo^ HLA-DR^−^ CD33^+^                          ARG1, iNOS, MMP-13, VEGF                          HCC         PBMCs      ([@B224])

  T-MDSCs          CD45^+^CD11b^+^ CD33^+^                              \-                                                CRC         TT         ([@B125])

  T-MDSCs          HLA-DR^−^ CD33^+^                                    \-                                                CRC         PBMCs/TT   ([@B124])

  T-MDSCs          CD33^+^CD45^+^CD13^+^CD14^−^ CD15^−^                 IDO, IL-4R                                        BC          PBMCs/TT   ([@B103])

  T-MDSCs          CD33^+^CD11b^+^CD14^−^                               ![](fimmu-11-01680-i0001.jpg)IL-6\                BC          PBMCs      ([@B104])
                                                                        ![](fimmu-11-01680-i0002.jpg)IL-12, INF-γ                                

  T-MDSCs          HLA-DR^−^ CD33^+^CD11b^+^                            ![](fimmu-11-01680-i0002.jpg)INF-γ                HCC         PBMCs/TT   ([@B217], [@B218])

  M-MDSCs          HLA-DR^−/low^CD14^+^                                 HMGB1, ARG1, S100P, MMP-9, MMP-25\                BC          PBMCs      ([@B92], [@B105], [@B106])
                                                                        ROS                                                                      

  M-MDSCs          HLA-DR^−/low^CD14^+^                                 \-                                                PC          PBMCs      ([@B39], [@B191])

  M-MDSCs          HLA-DR^−/low^CD14^+^                                 ![](fimmu-11-01680-i0002.jpg)INF-γ\               HCC         PBMCs/TT   ([@B213], [@B219], [@B220])
                                                                        ![](fimmu-11-01680-i0001.jpg)IL-10, IL-13, VEGF                          

  M-MDSCs          HLA-DR^−/low^CD14^+^                                 Nkp30 blocking                                    HCC         PBMCs/TT   ([@B223])

  M-MDSCs          HLA-DR^−/low^CD14^+^                                 gp91phox                                          NSCLC       PBMCs      ([@B242])

  M-MDSCs          CD33^+^CD11b^+^ HLA-DR^−^ CD14^+^CD15^−^             ARG1, CD39, iNOS, CXCR4                           CRC         PBMCs/TT   ([@B126])

  M-MDSCs          CD33^+^CD11b^+^ HLA-DR^−/low^ CD14^+^                TGF-β                                             MEL         PBMCs      ([@B140]--[@B142])

  M-MDSCs          CD33^+^CD11b^+^ HLA-DR^−/low^ CD14^+^ CD15^−^        \-                                                HCC         PBMCs/TT   ([@B216])

  M-MDSCs          CD33^+^CD11b^+^ HLA-DR^−^CD14^+^                     \-                                                HCC         PBMCs/TT   ([@B221])

  M-MDSCs          CD11b^+^CD14^+^S100A9^+^                             ARG1, iNOS, IL-4Rα, IL-10                         NSCLC       PBMCs      ([@B224])

  M-MDSCs          CD16^low^CD33^+^CD11b^+^ HLA-DR^−^ CD14^+^CD15^+^    ARG1, ROS                                         NSCLC       PBMCs      ([@B245])

  M-MDSCs          CD11b^+^ HLA-DR^−/low^ CD14^+^ CD15^−^               CCR5, PDL-1                                       NSCLC       TT         ([@B247])

  M-MDSCs          Lin^−^CD11b^+^ CD14^+^ CD73^+^ CD39^+^               IL-4R, HIF-1α, IL-10, COX-2                       NSCLC       PBMCs/TT   ([@B254])

  G-MDSCs          HLA-DR^−/low^CD15^+^                                 \-                                                BC          PBMCs      ([@B105])

  G-MDSCs          CD15^+^                                              ARG1                                              BC          TT         ([@B107])

  G-MDSCs          CD33^+^CD11b^+^ HLA-DR^−^ CD17^+^CD15^+^             ![](fimmu-11-01680-i0001.jpg)ROS; PDL-1           CRC         PBMCs/TT   ([@B126])

  G-MDSCs          CD33^+^CD11b^+^ HLA-DR^−/low^ CD15^+^                ARG1                                              CRC         PBMCs/TT   ([@B127])

  G-MDSCs          CD33^+^CD11b^+^ HLA-DR^−^ CD14^−^                    \-                                                MEL         PBMCs      ([@B142])

  G-MDSCs          CD33^low^CD11b^+^ HLA-DR^−/low^ CD14^−^CD15^+^       \-                                                MEL         PBMCs      ([@B143])

  G-MDSCs          CD33^+^CD11b^+^ HLA-DR^−^ CD14^−^                    ![](fimmu-11-01680-i0001.jpg)IL-6, IL-8           PC          PBMCs      ([@B190])

  G-MDSCs          CD33^+^CD11b^+^CD15^+^                               IL-23                                             PC          TT         ([@B186])

  G-MDSCs          CD33^+^CD11b^+^ HLA-DR^−/low^ CD14^−^CD15^+^         \-                                                HCC         PBMCs/TT   ([@B216])

  G-MDSCs          LOX-1^+^CD15^+^                                      ROS, ARG1                                         HCC         PBMCs/TT   ([@B222])

  G-MDSCs          CD33^+^CD11b^+^ CD14^−^CD15^+^                       ARG1, iNOS, IL-4R, INF-γR                         NSCLC       PBMCs      ([@B243])

  G-MDSCs          CD16^low^CD33^+^CD11b^+^ HLA-DR^−^ CD14^−^CD15^+^    ARG1, ROS                                         NSCLC       PBMCs      ([@B245])

  G-MDSCs          CD33^+^CD11b^+^ HLA-DR^−^ CD14^−^CD15^+^ILT3^high^   \-                                                NSCLC       PBMCs      ([@B246])

  G-MDSCs          CD11b^+^ HLA-DR^−/low^ CD14^−^ CD15^+^               CCR5, PDL-1                                       NSCLC       TT         ([@B247])

  G-MDSCs          Lin^−^CD11b^+^ CD14^−^ CD73^+^ CD39^+^               IL-4R, HIF-1α, IL-10, COX-2                       NSCLC       PBMCs/TT   ([@B254])
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*BC, breast cancer; CRC, colorectal cancer; HCC, hepatocellular carcinoma; MEL, melanoma; NSCLC, non-small cell lung cancer; PBMCs, peripheral blood mononuclear cells; PC, prostate cancer; TT, tumor tissue; M-MDSCs, monocytic-MDSCs; G-MDSCs, granulocytic-MDSCs; T-MDSCs, total-MDSCs*.

###### 

Summary of clinical trials targeting MDSCs in cancer patients.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Drug**                **Target**               **Combination partner**                **Tumor**        **[ClinicalTrials.gov](http://www.ClinicalTrials.gov) identifier**
  ----------------------- ------------------------ -------------------------------------- ---------------- --------------------------------------------------------------------
  ENTINOSTAT              class I HDAC             Nivolumab                              BC               NCT02453620

  IPI-549                 PI3K                     Nivolumab                              NSCLC, MEL, BC   NCT02637531

  IPI-549                 PI3K                     Tecentriq and Abraxane                 BC               NCT03961698

  REPARIXIN               CXCR2                    Paclitaxel                             BC               NCT02370238

  AB928                   A~2a~R and A~2b~R        IPI-549, PLD, NP                       BC               NCT03719326

  DS-8273a                TRAIL-R2                 Nivolumab                              CRC              NCT02076451

  PEXIDARTINIB            CSF1R                    Durvalumab                             CRC              NCT02777710

  MARAVIROC               CCR5                     \-                                     CRC              NCT01349036

  DANVATIRSEN (AZD9150)   STAT3                    \-                                     HCC              NCT01839604

  REGORAFENIB             multi-TKIs               Nivolumab                              HCC              NCT04170556

  ATRA                    Retinoic acid receptor   Ipilimumab                             MEL              NCT02403778

  SX682                   CXCR1/2                  Pembrolizumab                          MEL              NCT03161431

  RTA408                  Nrf-2                    Ipilimumab/Nivolumab                   MEL              NCT02259231

  Tasquinimod             S100A9                   \-                                     PC               NCT01234311

  AZD5069                 CXCR2                    Enzalutamide                           PC               NCT03177187

  Granocyte               G-CSF                    Cabazitaxel plus Prednisone            PC               NCT02961257

  RGX-104                 LXR                      Nivolumab/Ipilimumab/\                 NSCLC            NCT02922764
                                                   Docetaxel/Pembrolizumab                                 

  AB928                   A~2a~R and A~2b~R        Carboplatin/Pemetrexed Pembrolizumab   NSCLC            NCT03846310

  vinorelbine             Cytotoxic                Atezolizumab                           NSCLC            NCT03801304

  Oleclumab               CD73                     Durvalumab                             NSCLC            NCT04262388

  PD-0360324              CSF1                     Avelumab                               NSCLC, MEL, BC   NCT02554812

  ARRY-382                CSF1R                    Pembrolizumab                          NSCLC, MEL,      NCT02880371
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*AR, adenosine receptor; BC, breast cancer; CCR5, C-C chemokine receptor type 5; CXCR1/2, C-X-C motif chemokine receptor 1/2; CRC, colorectal cancer; CSF1, colony-stimulating factor 1; CSF1R, colony-stimulating factor 1 receptor; G-CSF, granulocyte colony-stimulating factor; HCC, hepatocellular carcinoma; HDAC, histone deacetylase; LXR, liver X receptor; MEL, melanoma; NP, nanoparticle albumin-bound paclitaxel; Nrf-2, nuclear factor erythroid 2-related factor 2; NSCLC, non-small cell lung cancer; PC, prostate cancer; PI3K, phosphatidylinositol 3-kinase; PLD, pegylated liposomal doxorubicin; STAT3, signal transducer and activator of transcription-3; TKIs, tyrosine kinase inhibitors; TRAIL-R2, TNF-related apoptosis-induced ligand receptor 2*.
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